PROMETHEUS^® IBS Diagnostic is the First Blood-Based Biomarker Test for IBS

Prometheus

Prometheus continues to deliver innovation in its therapeutics and diagnostics for physicians and their patients who suffer from gastrointestinal diseases.

PROMETHEUS IBS Diagnostic

• The first blood-based biomarker test for IBS
• Provides clear, simple test results to complement the clinical evaluation
• Can help clarify or validate other diagnostic findings
• Delivers tangible evidence to help reassure patients

Irritable Bowel Syndrome (IBS)

IBS is frequently encountered and can be difficult to diagnose

• Affects up to 20% of the US population
• The most common GI diagnosis among gastroenterology practices
• Affects 3.2 times more women than men
• No visible abnormality seen upon endoscopy
• Patients with IBS often go undiagnosed for several years
• Symptoms can resemble other conditions

IBS has been a diagnosis of exclusion

• Many tests are often performed to exclude other diseases
• Rome criteria effectiveness is influenced by subjective information received from patients
• A lack of objective evidence can make an IBS diagnosis difficult for patients to accept

For more information, please go to www.prometheuslabs.com